DexComTM Schedules Conference Call to Discuss Approval and Launch of Its Recently Approved 7-Day STS® Continuous Glucose Monitoring System
SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) today announced that management will hold a conference call to discuss the approval and launch of the SEVEN™ Continuous Glucose Monitoring System. The call will occur on Monday, June 11, 2007 at 1:30 pm (PDT).
To listen to the conference call, please dial (888) 422-7124 - (US/Canada) or (334) 240-1633 (International) and use the participant code "490034" approximately five minutes prior to the start time.
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, California, is developing and marketing continuous glucose monitoring systems for people with diabetes.
Cautionary Statement Regarding Forward Looking Statements
DexCom is a medical device company with a limited operating history. Successful commercialization of the company’s products is subject to numerous risks and uncertainties, including a lack of acceptance in the marketplace by physicians and patients, the inability to manufacture products in commercial quantities at an acceptable cost, possible delays in the company’s development programs, the inability of patients to receive reimbursements from third-party payors and inadequate financial and other resources. Certain of these risks and uncertainties, in addition to other risks, are more fully described in the company’s quarterly report on Form 10-Q for the period ending March 31, 2007, as filed with the Securities and Exchange Commission on May 9, 2007.